Claims for Patent: 10,039,810

Summary for Patent: 10,039,810

Title:	Pharmaceutical compositions and methods for fabrication of solid masses comprising anti-interleukin antibodies
Abstract:	Embodiments of the invention provide shaped masses comprising one or more drugs such as proteins or polypeptides and methods for forming such shaped masses. One embodiment provides a shaped mass comprising a drug such as a protein or polypeptide having a biological activity in the body of a mammal. The shaped mass is formed by compression of a precursor material comprising the drug wherein an amount of biologically active drug in the mass is a preserved above a minimum level. Drugs which may be incorporated into the shaped mass may include one or more glucose regulating proteins such as insulin, incretins; and immunoglobulins such as TNF-inhibiting antibodies or interleukin neutralizing antibodies. Embodiments of the shaped mass may be incorporated into a tissue penetrating member which is inserted into the intestinal wall allowing for the oral delivery of proteins and peptides which would otherwise be degraded in the intestinal tract.
Inventor(s):	Morales; Mercedes (San Francisco, CA), Imran; Mir (Los Altos Hills, CA), Korupolu; Radhika (Fremont, CA), Hashim; Mir (Fremont, CA)
Assignee:	InCube Labs, LLC (San Jose, CA)
Application Number:	14/714,136
Patent Claims:	1. A shaped mass comprising an interleukin neutralizing antibody (AI-antibody), the shaped mass formed by compression of a precursor material comprising the AI-antibody, wherein at least about 65% of the AI-antibody in the shaped mass has affinity for an epitope on an interleukin molecule, wherein the AI-antibody is an immunoglobulin G (IgG), the shaped mass having a density in a range of about 0.80 to about 1.10 mg/mm.sup.3. 2. The shaped mass of claim 1, wherein the density is in a range of about 0.85 to about 1.05 mg/mm.sup.3. 3. The shaped mass of claim 1 wherein the density is in a range of about 1.00 to about 1.01 mg/mm.sup.3. 4. The shaped mass of claim 1, wherein the precursor material has a particle size in a range of about 100 to 400 .mu.m. 5. The shaped mass of claim 1, wherein at least about 80% of AI-antibody in the shaped mass has affinity for an epitope on an interleukin molecule. 6. The shaped mass of claim 1, wherein the AI-antibody comprises an antibody to a member of the interleukin-17 family of cytokines. 7. The shaped mass of claim 6, wherein the AI-antibody is secukinumab. 8. The shaped mass of claim 6, wherein the AI-antibody is ixekizumab. 9. The shaped mass of claim 6, wherein the AI-antibody is brodalumab. 10. The shaped mass of claim 6, wherein a dose of AI-antibody in the shaped mass is in a range from about 1 to 5 mg. 11. The shaped mass of claim 1, wherein the compression is performed in a mold or fixture. 12. The shaped mass of claim 1, wherein the shaped mass is formed by compression of a powder comprising the AI-antibody. 13. The shaped mass of claim 1, wherein the shaped mass has a pellet or cylindrical shape. 14. The shaped mass of claim 1, wherein the shaped mass has a tablet shape. 15. The shaped mass of claim 1, wherein the shaped mass is configured to penetrate and be inserted into the wall of the small intestine by the application of force. 16. The shaped mass of claim 1, wherein the shaped mass comprises a pharmaceutical excipient. 17. The shaped mass of claim 16, wherein the pharmaceutical excipient comprises at least one of a lubricant, a binding agent, a bulking agent or polyethylene glycol (PEG). 18. A shaped mass comprising an AI-antibody, the shaped mass formed by compression of a precursor material comprising the AI-antibody, wherein at least about 65% of the AI-antibody in the shaped mass has affinity for an epitope on an interleukin molecule, wherein the AI-antibody is an immunoglobulin G (IgG), and wherein the precursor material has a particle size in a range of about 50 to 450 .mu.m. 19. The shaped mass of claim 18, wherein the precursor material has a particle size in the range of 100 to 400 .mu.m. 20. The shaped mass of claim 18, wherein the shaped mass has a density in a range of about 0.80 to about 1.10 mg/mm.sup.3. 21. The shaped mass of claim 18, wherein the AI-antibody comprises an antibody to a member of the interleukin-17 family of cytokines. 22. The shaped mass of claim 21, wherein the AI-antibody is secukinumab. 23. The shaped mass of claim 21, wherein the AI-antibody is ixekizumab. 24. The shaped mass of claim 21, wherein the AI-antibody is brodalumab. 25. The shaped mass of claim 21, wherein a dose of AI-antibody in the shaped mass is in a range from about 1 to 5 mg.

Details for Patent 10,039,810

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Novartis Pharmaceuticals Corporation	COSENTYX	secukinumab	Injection	125504	January 21, 2015	10,039,810	2034-05-15
Novartis Pharmaceuticals Corporation	COSENTYX	secukinumab	For Injection	125504	January 21, 2015	10,039,810	2034-05-15
Novartis Pharmaceuticals Corporation	COSENTYX	secukinumab	Injection	125504	May 28, 2021	10,039,810	2034-05-15
Novartis Pharmaceuticals Corporation	COSENTYX	secukinumab	Injection	125504	May 11, 2023	10,039,810	2034-05-15